Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies

Schulz, Wolfgang A.; Krummeck, Angelika; Rösinger, Ingrid; Eickelmann, Peter; Neuhaus, Christine; Ebert, Thomas; Schmitz‐Dräger, Bernd J.; Sies, Helmut

doi:10.1097/00008571-199706000-00008

Cited by 132 publications

(88 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After further retrieved, 12 articles were excluded because of the following reasons: three were for review or meta-analysis articles (Gonzalez, 1997;Chao et al, 2006;Ersoy Tunali et al, 2011); one did not focus on the NQO1 rs1800566 polymorphism but on NQO2 (exon 3, T14055C) polymorphism (Wen et al, 2009); two were for the correlation between the NQO1 rs1800566 polymorphism and NQO1 activity (Basu et al, 2004;Jamieson et al, 2007); two were for the correlation between the NQO1 rs1800566 polymorphism and p53 mutations (Martone et al, 2000;Ryk et al, 2006); one was for the correlation between the NQO1 rs1800566 polymorphism and clinical course of bladder cancer (Sanyal et al, 2007); Three studies did not report gene frequencies (Vineis et al, 2007;Dhaini et al, 2012;Ersoy Tunali et al, 2012). Therefore, 12 studies (Schulz et al, 1997;Choi et al, 2003;Park et al, 2003;Hung et al, 2004;Moore et al, 2004;Sanyal et al, 2004;Broberg et al, 2005;Terry et al, 2005;Figueroa et al, 2008;Wang et al, 2008;Paonessa et al, 2009;Pandith et al, 2011) were included in our meta-analysis. The detailed characteristics of the included studies were shown in Table 2.…”

Section: Characteristics Of All Included Studiesmentioning

confidence: 99%

The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects

Guo¹,

Feng²

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Section: Characteristics Of All Included Studiesmentioning

confidence: 99%

The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects

Guo¹,

Feng²

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Hence, differences in the quality and quantity of NQO enzymes are likely to have a significant influence on the susceptibility to various common diseases, including arteriosclerosis, hypertension, and diabetes mellitus, as well as cancer. In fact, a Pro203Ser amino-acid substitution in the NQO1 gene has been implicated as a factor influencing risk for lung cancer (Rosvold et al 1995;Chen et al 1999;Lin et al 1999), cutaneous basal cell carcinoma (Clairmont et al 1999), and urological malignancy (Schulz et al 1997). In addition, this change appears to be associated with risk for a subtype of colon cancer characterized by mutation at codon 12 of the K-ras gene (Lafuente et al 2000).…”

Section: Quinone Oxidoreductasesmentioning

confidence: 99%

Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes

et al. 2001

View full text Add to dashboard Cite

Single nucleotide polymorphisms (SNPs) in genes encoding drug-metabolizing enzymes, transporters, receptors, and other drug targets have been widely implicated as contributors to differences among individuals as regards the efficacy and toxicity of many medications, as well as the susceptibility to complex diseases. By combining the polymerase chain reaction (PCR) technique with direct sequencing, we screened genomic DNAs from 48 Japanese volunteers for SNPs in genes encoding three quinone oxidoreductases (NQO1, NQO2, and PIG3) and 17 sulfotransferases (SULT1A1, SULT1A2, SULT1A3, SULT1C1, SULT1C2, SULT2A1, SULT2B1, ST1B2, TPST1, TPST2, SULTX3, STE, CST, CHST2, CHST4, and CHST5). In all, we identified 320 SNPs from these 20 loci: 22 within coding elements, 21 in 5Ј flanking regions, 10 in 5Ј untranslated regions, 223 in introns, 19 in 3Ј untranslated regions, and 25 in 3Ј flanking regions. The ratio of transitions to transversions was approximately 2.3 to 1. Of the 22 coding SNPs, 6 were nonsynonymous substitutions that resulted in amino-acid substitutions. The highdensity SNP maps we constructed from this data for each of the quinone oxidoreductases and sulfotransferases examined here should provide useful information for investigations designed to detect association(s) between genetic variations and common diseases or responsiveness to drug therapy.

show abstract

“…DNA was extracted and characterized from powdered frozen tissues or from leukocytes as described (Jürgens et al, 1996;Schulz et al, 1997). Two microsatellite markers, D11S1318 and D11S922, were used for LOH analysis.…”

Section: Dna Extraction and Loh Analysismentioning

confidence: 99%

Decreased expression of p57KIP2 mRNA in human bladder cancer

Oya

Schulz

2000

Br J Cancer

View full text Add to dashboard Cite

Summary To identify targets of genetic and epigenetic alterations on chromosome 11p15.5 in human bladder cancer, expression of the imprinted KIP2, IGF2 and H19 genes was studied by quantitative RT-PCR in 24 paired samples of urothelial carcinomas and morphologically normal mucosa obtained by cystectomy, and in bladder carcinoma cell lines. The most frequent alteration in tumour tissue was decreased expression of KIP2 identified in 9/24 (37%) specimens. Decreased IGF2 and H19 mRNA levels were found in five (21%) and three (13%) tumours, respectively. One tumour each overexpressed IGF2 and H19. Loss of H19 expression was only found associated with loss of KIP2 expression, whereas decreased expression of IGF2 mRNA occurred independently. Almost all bladder carcinoma cell lines showed significant changes in the expression of at least one gene with diminished expression of KIP2 mRNA as the most frequent alteration. IGF2 mRNA levels were diminished in several lines, but increased in others. The KIP2 gene could be an important target of genetic and epigenetic alterations in bladder cancer affecting the maternal chromosome 11p15.5. However, reminiscent of the situation in Wilms' tumours, expression of the IGF2 gene on the paternal chromosome can also be disturbed in bladder cancers.

show abstract

Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies

Cited by 132 publications

References 0 publications

The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects

The NQO1 rs1800566 Polymorphism and Risk of Bladder Cancer: Evidence from 6,169 Subjects

Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes

Decreased expression of p57KIP2 mRNA in human bladder cancer

Contact Info

Product

Resources

About